• Award recognises excellence in vaccine manufacturing
    WuXi Vaccines was named 'Best Vaccine CMO of the Year' at the 2023 Asia-Pacific Vaccine Excellence Awards.

Company News

Award recognises excellence in vaccine manufacturing

Jan 02 2024

WuXi Vaccines, a leading global Contract Development and Manufacturing Organisation (CDMO) specialising in vaccines, has been awarded the title of 'Best Vaccine CMO of the Year' for the second consecutive year at the 2023 Asia-Pacific Vaccine Excellence Awards (AVEA).

The AVEA 2023 event was dedicated to acknowledging outstanding achievements in the vaccine and supply chain sector in Asia. Award winners were determined through voting by industry experts, professionals, and stakeholders in the vaccine community. WuXi Vaccines distinguished itself among the nominees for its commitment to advancing global vaccine accessibility, particularly in low and middle-income countries.

Mr Jian Dong, CEO of WuXi Vaccines, expressed gratitude, stating: "We are deeply honoured to receive the 'Best Vaccine CMO Award of the Year' for the second year. This prestigious accolade serves as a testament to WuXi Vaccines' commitment to furthering global health initiatives by providing end-to-end solutions that enable our partners to bring vital vaccine products to the market more efficiently."

WuXi Vaccines has played a pivotal role in the battle against COVID-19 by manufacturing hundreds of millions of doses of the COVID-19 vaccine, facilitating distribution to over 180 countries. The recent launch of its standalone vaccines CDMO site in Suzhou, China, marked a significant milestone, passing an on-site GMP audit by a global vaccine leader. This achievement is expected to accelerate global client projects by offering high-quality end-to-end services for a diverse range of vaccines. Meanwhile, the Dundalk facility in Ireland achieved significant milestones, including the initiation of Tech Transfer (TT) and notable progress in commissioning qualification and validation (CQV) activities. The QC potency lab at the facility became operational in July 2020 and received the GMP certificate from the Ireland Health Products Regulatory Authority (HPRA) in July 2022.  

More information online

Digital Edition

Lab Asia 31.2 April 2024

April 2024

In This Edition Chromatography Articles - Approaches to troubleshooting an SPE method for the analysis of oligonucleotides (pt i) - High-precision liquid flow processes demand full fluidic c...

View all digital editions


ASMS Conference

Jun 02 2024 Anaheim, CA, USA


Jun 10 2024 Frankfurt, Germany

Lab & Test Asia

Jun 12 2024 Bangkok, Thailand

Chemspec Europe 2024

Jun 19 2024 Dusseldorf, Germany

Forensics Europe Expo

Jun 19 2024 London, UK

View all events